---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-246370"
form_type: "8-K"
ticker: "IKT"
cik: "0001750149"
company_name: "Inhibikase Therapeutics, Inc."
filed_at: "2022-09-16T23:59:59+00:00"
generated_at: "2026-06-23T09:09:37.381329+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Inhibikase Therapeutics presents Phase 1/1b data for IkT-148009 in Parkinson's; Phase 2 ongoing

## Summary
- Phase 1/1b of IkT-148009 (88 healthy, 13 PD patients) showed no clinically significant AEs, linear PK, and CNS penetration over 12.5-325 mg daily doses.
- In PD mouse models, once-daily oral IkT-148009 preserved >80% SNpc neurons, improved motor function, and reduced pathological alpha-synuclein aggregates.
- C-Abl activation is required for PD initiation; IkT-148009 is a selective brain-penetrant c-Abl inhibitor with no organ toxicity seen in toxicology studies.
- Phase 2 3-month dosing study (NCT05424276) in mild-to-moderate PD patients has begun to evaluate efficacy and disease modification.

## SEC filing metadata
- accession: 0001193125-22-246370
- form_type: 8-K
- ticker: IKT
- cik: 0001750149
- company_name: Inhibikase Therapeutics, Inc.
- filed_at: 2022-09-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1750149/000119312522246370/0001193125-22-246370-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1750149/000119312522246370/d386213d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-246370
- JSON: https://secwatch.observer/filing/0001193125-22-246370.json
- Plain text: https://secwatch.observer/filing/0001193125-22-246370.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.